AtriCure (ATRC) EBITDA (2010 - 2026)

AtriCure (ATRC) has 17 years of EBITDA data on file, last reported at $526000.0 in Q1 2026.

• On a quarterly basis, EBITDA rose 108.83% year-over-year to $526000.0 in Q1 2026; TTM through Mar 2026 was -$3.0 million, a 91.53% increase from a year earlier, with the FY2025 full-year figure at -$9.4 million, up 76.39% from the prior year.
• EBITDA for Q1 2026 stood at $526000.0, down from $2.5 million in the prior quarter.
• Over the last five years, EBITDA for ATRC reached as high as $2.5 million in Q4 2025 and fell as low as -$14.5 million in Q4 2024.
• Historically, EBITDA has averaged -$7.0 million across 5 years, with a median of -$7.2 million in 2024.
• Across the five-year window, EBITDA slumped 110.87% in 2022 and surged 117.15% in 2025, its largest moves.
• Year by year, EBITDA stood at -$4.1 million in 2022, then plunged by 109.57% to -$8.7 million in 2023, then tumbled by 67.55% to -$14.5 million in 2024, then jumped by 117.15% to $2.5 million in 2025, then tumbled by 78.88% to $526000.0 in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $526000.0 in Q1 2026, $2.5 million in Q4 2025, and $208000.0 in Q3 2025.